{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric, a specific numeric value for that metric, and a unit for that value."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nMice received intraperitoneal administration of phosphate buffered saline (PBS), ASP2138 (0.01 mg/kg) or saline on days 0 and 7, and PBS or DC101 (200 pg/head) on days 0, 3, 7 and 10.\nMice received intraperitoneal administration of phosphate buffered saline (PBS), ASP2138 (0.01 mg/kg), saline or PTX (10 mg/kg) on days 0 and 7, and PBS or DC101 (200 pg/head) on days 0, 3, 7 and 10.\nMice received intraperitoneal administration of phosphate buffered saline (PBS), ASP2138 (0.01 mg/kg), saline or PTX (10 mg/kg) on days 0 and 7, and PBS or DC101 (200 pg/head) on days 0, 3, 7 and 10."}
{"final_json": [{"molecule_name": "ASP2138", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.01", "unit": "mg/kg"}, {"molecule_name": "DC101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "200", "unit": "pg/head"}, {"molecule_name": "ASP2138", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.01", "unit": "mg/kg"}, {"molecule_name": "PTX", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "mg/kg"}, {"molecule_name": "DC101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "200", "unit": "pg/head"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nPreferably, the term \"significant affinity\" refers to the binding to a predetennined target with a dissociation constant (KD) of IO\u2019<sup>5</sup> M or lower, 1(T<sup>6</sup> M or lower, IO\"<sup>7</sup> M or lower, IO\u2019<sup>8</sup> M or lower, IO'<sup>9</sup> M or lower, IO\u2019<sup>10</sup> M or lower, IO\u2019<sup>11</sup> M or lower, or 10\u2019<sup>12</sup> M or lower.\nFor example, if the KD for binding of an agent to the target to which the agent is capable of binding is IO\u2019<sup>7</sup> M, the KD for binding to a target for which the agent has no significant affinity would be at least 1 O\u2019<sup>6</sup> M, 1 O\u2019<sup>5</sup> M, 10\"<sup>4</sup> M, 10\u2019<sup>3</sup> M, IO\u2019<sup>2</sup> M, or 10<sup>4</sup> M.\nPreferably, a binding agent is specific for a predetermined target if it binds to said target with a KD that is at least 10-fold, 100-fold, 10<sup>3</sup>-fold, 10<sup>4</sup>-fold, 10<sup>5</sup>-fold, or 10<sup>6</sup>-fold lower than the KD for binding to a target for which it is not specific.\nFor example, if the KD for binding of a binding agent to the target for which it is specific is 10\u2019<sup>7</sup> M, the KD for binding to a target for which it is not specific would be at least 10\"<sup>6</sup> M, 10\u2019<sup>5</sup> M, 10\u2019<sup>4</sup> M, 10\"<sup>3</sup> M, 10\"<sup>2</sup> M, or 10\"<sup>1</sup> M.\nThe term \"KD\" (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction.\nThus, measurements of affinity and other antigen-binding parameters, e.g., KD, IC50, are preferably made with standardized solutions of binding agent and antigen, and a standardized buffer."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^5", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^6", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^7", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^8", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^9", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^10", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^11", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "<10^12", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^7", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^6", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^5", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^4", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^3", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^2", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "KD", "value": "10^1", "unit": "M"}]}
{"raw_mentions": "In some embodiments, the antibody binds VEGFR2 with a Kd value of between about 100 nM and about 1 pM. \nIn one embodiment, Kd is measured by a RIA performed with an anti- VEGFR2 Ab, preferably ramucirumab."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": "VEGFR2", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "between about 100 nM and about 1 pM", "unit": null}, {"molecule_name": "ramucirumab", "protein_target_name": "VEGFR2", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nMice received intraperitoneal administration of ASP2138 (0.01 mg/kg) and saline on days 0 and 7, and intraperitoneal administration of PBS on days 0, 3, 7 and 10.\nMice received intraperitoneal administration of DC101 at 200 pg/head on days 0, 3, 7 and 10.\nMice received intraperitoneal administration of PBS and PTX (10 mg/kg) on days 0 and 7, and intraperitoneal administration \nB16-F10_mCLDN18.2 cells were suspended in PBS at 4.0 x 10<sup>6</sup> cells/mL and subcutaneously inoculated into the flank of 7-week-old mice at 2.0 x 10<sup>5</sup> cells/50 pL/ mouse and allowed to grow."}
{"final_json": [{"molecule_name": "ASP2138", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.01", "unit": "mg/kg"}, {"molecule_name": "DC101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "200", "unit": "pg/head"}, {"molecule_name": "PTX", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "mg/kg"}, {"molecule_name": "B16-F10_mCLDN18.2", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "4.0 x 10^6", "unit": "cells/mL"}, {"molecule_name": "B16-F10_mCLDN18.2", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "2.0 x 10^5", "unit": "cells/50 pL/mouse"}]}
{"raw_mentions": "The tumor growth was inhibited by the administration of ASP2138 or DC101 by 66% or 61% on day 14, respectively.\nThe combination of ASP2138 and DC 101 (combination!) inhibited the tumor growth by 95% on day 14, and no differences in body weight change were observed among the groups (Table 2, Figures 2 and 3).\nThe administration of DC101 and PTX (DC101-PTX) inhibited the tumor growth by 76% on day 14.\nThe combination of ASP2138 and DC101-PTX (combination^) inhibited the tumor growth by 93% on day 14, and no differences in body weight change were observed among the groups (Table 2, Figures 4 and 5)."}
{"final_json": [{"molecule_name": "ASP2138", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "66%", "unit": null}, {"molecule_name": "DC101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "61%", "unit": null}, {"molecule_name": "ASP2138 and DC 101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "95%", "unit": null}, {"molecule_name": "DC101-PTX", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "76%", "unit": null}, {"molecule_name": "ASP2138 and DC101-PTX", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "93%", "unit": null}]}
